Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02891538 · ClinicalTrials.gov registry record · Early Phase 1
Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients
A Early Phase 1 study of Colon Cancer, sponsored by The University of Texas Health Science Center at San Antonio.
- Active
- Registry status
- Early Phase 1
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT02891538: Active Early Phase 1 study of Colon Cancer, sponsored by The University of Texas Health Science Center at San Antonio.
NCT02891538 is a Early Phase 1 study of Colon Cancer that is active but no longer recruiting, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 51 participants, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02891538, a Early Phase 1 study of Colon Cancer, is active but no longer recruiting, sponsored by The University of Texas Health Science Center at San Antonio.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a randomized, controlled pilot trial of patients with histological documentation of primary colon or rectal adenocarcinoma with resectable cancer, who have not received any treatments for cancer. If patient is a candidate for surgical resection, with no planned neoadjuvant chemotherapy, then the patient is eligible. All eligible subjects will be consented prior to surgery.
Conditions Studied
Interventions
- DRUG Epigallocatechin gallate (EGCG)
Study Locations (1)
Texas
- UT Health San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2017-01-31 |
| Est. Completion | 2025-12-02 |
| Phase | Early Phase 1 |
What the registry record for NCT02891538 still lists
NCT02891538 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Colon Cancer appearing as the primary indexed condition, and to 1 intervention - of which Epigallocatechin gallate (EGCG) is the first listed.
NCT02891538 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02891538 about?
NCT02891538 is a clinical study titled "Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients". This will be a randomized, controlled pilot trial of patients with histological documentation of primary colon or rectal adenocarcinoma with resectable cancer, who have not received any treatments for cancer. If patient is a candidate for surgical resection, with no planned neoadjuvant chemotherapy,...
What is the current status of trial NCT02891538?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 51 participants. The study started on 2017-01-31. Estimated completion is 2025-12-02.
What conditions does trial NCT02891538 study?
This clinical trial studies the following conditions: Colon Cancer.
What interventions are being tested in trial NCT02891538?
The interventions under investigation include: Epigallocatechin gallate (EGCG) (DRUG).
Who is sponsoring clinical trial NCT02891538?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02891538 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02891538's enrollment target sits among peer trials
51 66th of 97 higher than 31 of 97 other Colon Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colon Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
-
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI